Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
One Percent Rule Checklist For Safer Forex Trading Risk 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
NEW YORK, April 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD, Inc. ("TherapeuticsMD") (NYSEMKT:TXMD) securities between July 7, 2016 and April 9, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-0004HR NDA.
If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
